03 · What You Need to Know
Possession, Ownership, Control, and Rights Are Different Questions
Start by asking what exactly is supposedly owned
A stored biospecimen project can involve several distinct objects and interests. There is the physical tube, slide, tissue block, blood sample, extracted DNA, or cell culture. There may also be clinical information, research measurements, sequence files, processed datasets, algorithms, publications, inventions, patents, and commercial products.
A legal rule governing the physical specimen does not automatically determine rights in all of these downstream materials.
Physical specimen
The biological material itself, such as blood, tissue, cells, saliva, extracted DNA, or another stored specimen.
Derived data
Information generated by analyzing the specimen, such as sequence data, assay results, measurements, images, or other research observations.
Intellectual property
Potentially protectable inventions or other intellectual creations arising from research, governed by applicable intellectual-property law and agreements.
Physical custody is not necessarily legal ownership
A hospital pathology department may physically possess tissue. A biobank may store it. A university may control the freezer. None of those facts alone tells you the complete legal relationship between the institution and the person from whom the specimen came.
Custody describes who holds or manages material. Ownership is a legal concept that can involve rights to possess, transfer, exclude others, destroy, or otherwise control property. Different jurisdictions may characterize human biological material differently, and consent or repository agreements may define practical control without resolving every theoretical property question.
Researchers should therefore avoid statements such as “the university owns your tissue” unless that claim is actually supported by applicable law and the governing agreements.
Donors can retain important interests without owning the specimen as ordinary property
A participant may have consent rights, withdrawal options, privacy protections, confidentiality expectations, restrictions on future use, and rights to receive specified information even when the legal system does not treat the stored specimen as property owned by that participant in the conventional sense.
Conversely, describing someone as the “donor” should not be interpreted as meaning that every continuing ethical interest vanished at the moment the specimen was provided.
The relationship is therefore poorly captured by a binary question of “Who owns it?”
Consent can define use without transferring every conceivable right
Research consent commonly explains what investigators may do with a specimen, whether it may be stored, shared, used in future studies, used commercially, or retained for a particular period.
Those provisions establish authorization and expectations. They do not necessarily constitute a comprehensive property-law agreement.
HHS advisory guidance recommends that consent for stored specimens address issues including sponsorship, disposition of samples, who will have access, how specimens will be used, and potential commercialization. It also advises informing participants about the extent to which they can expect to control or receive compensation from future commercial uses.
Commercialization does not automatically create a donor right to profits
A specimen may contribute to a discovery with commercial value. That possibility understandably raises a question: if part of my body helped create the product, am I entitled to part of the profit?
There is no universal rule giving specimen contributors a share of downstream commercial revenue. The answer depends on applicable law, consent, contracts, benefit-sharing arrangements, and the circumstances of the research.
The U.S. Common Rule requires informed consent, when research involves collection of biospecimens, to include a statement indicating whether the specimens may be used for commercial profit and whether the subject will or will not share in that commercial profit.
The point is disclosure, not a regulatory promise that contributors necessarily receive payment.
Derived data can be governed differently from the specimen
Once researchers sequence DNA or perform another assay, they have created data. The physical specimen might later be destroyed while the resulting sequence files remain in databases for years.
Rights and responsibilities concerning those data may arise from privacy law, research consent, repository policy, database-access conditions, contractual agreements, data-sharing rules, and intellectual-property law rather than from whatever property status applies to the physical sample.
This distinction becomes especially important when participants later seek withdrawal. Removing a remaining tube from a freezer and retracting data already incorporated into analyses, shared databases, or publications are technically and ethically different actions.
Research findings are not necessarily owned in the same way as raw specimens
Researchers transform biological material through scientific labor, interpretation, and analysis. A biomarker model, laboratory method, manuscript, database, or invention may involve contributions from investigators, institutions, funders, collaborators, and technology developers.
The resulting rights may therefore be governed by employment agreements, funding conditions, intellectual-property policies, collaboration agreements, patent law, copyright law, database rules, or other arrangements.
None of this means that donor interests disappear. It means that the relationship between source material and downstream knowledge cannot be reduced to “I supplied the tissue, therefore I own every later result” or its opposite, “we possess the tissue, therefore the donor has no continuing interests.”
Control may be more useful than ownership for everyday research decisions
For researchers, many practical disputes concern control rather than ultimate legal title. Who decides whether a secondary investigator receives specimens? Who can approve destructive testing? Who may link specimen data with clinical records? Who keeps the coding key? Who decides when material is destroyed?
Repositories commonly answer these questions through governance rules, access committees, ethics review, consent restrictions, material-transfer agreements, and institutional policies.
A biobank can therefore exercise substantial stewardship and access control even when the philosophical or legal question of “ownership” is more complicated.
Sharing a specimen does not necessarily transfer unrestricted control
A repository may provide a specimen to another research institution under a material transfer agreement or comparable arrangement. The receiving researcher may be permitted to perform only specified analyses, may be prohibited from redistributing the material, and may need to destroy or return unused portions.
Physical possession by the recipient therefore does not necessarily imply unrestricted ownership.
The donor's original choices can continue to constrain downstream use
If a participant consented only to particular categories of research, those restrictions can remain relevant when material is transferred or reused. HHS advisory guidance specifically notes that institutions may have an obligation to honor agreements made with participants about specimen use even where secondary research with coded or non-readily-identifiable specimens falls outside Common Rule human-subjects regulation.
This connects ownership and governance to whether stored specimens can be used for research the donor never anticipated. The institution's ability to possess or transfer a sample does not necessarily establish permission for every research purpose.
Withdrawal rights should not be inferred from ownership language alone
A participant might be allowed to request destruction of remaining identifiable specimens under the consent and repository policy without legally “owning” the specimens. Conversely, a property interest would not necessarily mean that every research consequence can be reversed once analyses have occurred.
The practical issue of withdrawing biological samples after analyses have already been performed therefore needs to be answered through the consent, governance, and stage of research rather than by invoking ownership as a shortcut.
Jurisdiction matters substantially
Property rights in human biological material are not governed by one global research rule. National and subnational law can differ, and particular kinds of specimens may be subject to special statutes or case law.
HHS advisory guidance explicitly notes that questions involving ownership, control, access, commercialization, and possession of stored specimens may be subject to state law in the United States and recommends that consent documents reflect applicable requirements.
For international collaborations, researchers should therefore identify the law governing collection, storage, transfer, intellectual property, and data processing rather than assuming that the rules of the receiving laboratory answer every question.
Watch Out
Avoid writing consent language that says participants “give up ownership” or institutions “own everything derived from the sample” unless the wording has been reviewed against applicable law and accurately describes the arrangement. Property language can imply much more than the research protocol actually requires.
